Asieris(SH:688176) Shang Hai Zheng Quan Bao·2026-01-22 18:48Core Viewpoint - Jiangsu Yahui Pharmaceutical Technology Co., Ltd. has received approval for the Phase I clinical trial of its product APL-2401 in Australia, which targets FGFR2/3-driven advanced solid tumors, marking a significant step in its international clinical research efforts [2][3]. Group 1: Drug Information - The drug APL-2401, also known as ASN-8639 tablets, is a highly selective small molecule inhibitor targeting FGFR2/3, aimed at providing new treatment options for patients with advanced solid tumors such as urothelial carcinoma, cholangiocarcinoma, endometrial cancer, gastric cancer, breast cancer, ovarian cancer, non-small cell lung cancer, and other specific solid tumors [3][4]. - APL-2401 demonstrates superior dual kinase inhibition activity compared to existing FGFR2 or FGFR3 selective inhibitors, showing enhanced tumor cell killing and modulation of the tumor microenvironment while significantly reducing side effects associated with FGFR1 and FGFR4 [4]. Group 2: Clinical Trial Approval - The clinical trial application for APL-2401 has already been approved by the National Medical Products Administration (NMPA) in China, and the company is actively advancing the product's international multi-center clinical research [2][5]. - The approval process for the clinical trial in Australia was expedited, with the application being processed in just 22 working days, making it one of the first projects to receive approval under the new policy aimed at optimizing the review and approval of innovative drugs [5]. Group 3: Market Impact - The recent approval for the Phase I clinical trial in Australia is not expected to have a significant impact on the company's short-term performance, as drug development is characterized by long cycles, multiple approval stages, and substantial investment [2][6].